Docgo INC. (DCGO) — SEC Filings

Q: What are the key financial highlights for Docgo INC.?

Key financial highlights for Docgo INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Docgo INC.?

Key executives at Docgo INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Docgo INC. stock?

Risk factors for Docgo INC. (DCGO) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Docgo INC.?

Forward-looking statements and predictions from Docgo INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Docgo INC.. Recent 8-K filing on Dec 12, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Docgo INC. on SEC EDGAR

Overview

Docgo INC. (DCGO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 12, 2025: DocGo Inc. filed an 8-K on December 12, 2025, to report current information. The filing does not contain specific details about new events, agreements, or financial figures, but serves as a standard disclosure.

Sentiment Summary

Across 30 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 26 neutral, 1 mixed. The dominant filing sentiment for Docgo INC. is neutral.

Filing Type Overview

Docgo INC. (DCGO) has filed 13 8-K, 6 10-Q, 1 8-K/A, 1 DEF 14A, 2 10-K, 1 SC 13D/A, 5 SC 13G/A, 1 DEFA14A with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (30)

DocGo Inc. Files 8-K Disclosure — 8-K · Dec 12, 2025 Risk: low
DocGo Inc. filed an 8-K on December 12, 2025, to report current information. The filing does not contain specific details about new events, agreements, or finan
DocGo's Revenue Halves, Plunging to $54M Loss Amid Impairment Charges — 10-Q · Nov 10, 2025 Risk: high
DocGo Inc. (DCGO) experienced a significant financial downturn for the nine months ended September 30, 2025, reporting a net loss of $54,026,555, a stark contra
DocGo Inc. Files Amendment to Form 8-K — 8-K/A · Oct 21, 2025 Risk: low
DocGo Inc. filed an amendment (Amendment No. 1) to its Form 8-K on October 21, 2025, reporting an event that occurred on October 20, 2025. The filing pertains t
DocGo Inc. Files 8-K with Material Agreement Details — 8-K · Oct 20, 2025 Risk: low
On October 20, 2025, DocGo Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes Regulation FD disclosures and financial
DocGo's Revenue Jumps 25% Amidst Q2 Net Loss — 10-Q · Aug 7, 2025 Risk: medium
DocGo Inc. reported a significant increase in revenue for the three months ended June 30, 2025, reaching $150.5 million, up from $120.3 million in the same peri
DocGo Inc. Reports Shareholder Vote Matters — 8-K · Jun 18, 2025 Risk: low
DocGo Inc. filed an 8-K on June 18, 2025, reporting on matters submitted to a vote of security holders on June 17, 2025. The filing does not detail the specific
DocGo Inc. Files 8-K for Regulation FD Disclosure — 8-K · Jun 12, 2025 Risk: low
On June 12, 2025, DocGo Inc. filed an 8-K report. The filing indicates that the company is providing a Regulation FD Disclosure. No specific financial figures o
DocGo Inc. Files Q1 2025 10-Q — 10-Q · May 8, 2025 Risk: low
DocGo Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly Motion Acquisition Corp., is based in New York and operates in health serv
DocGo Inc. Files 2025 Proxy Statement — DEF 14A · Apr 24, 2025 Risk: low
DocGo Inc. filed its definitive proxy statement (DEF 14A) on April 24, 2025, for its annual meeting on June 17, 2025. The filing details the company's governanc
DocGo Inc. Files 2024 10-K Report — 10-K · Feb 27, 2025 Risk: medium
DocGo Inc. filed its 2024 10-K report on February 27, 2025, detailing its financial performance for the fiscal year ending December 31, 2024. The company, forme
DocGo Inc. Files 8-K for Regulation FD Disclosure — 8-K · Dec 20, 2024 Risk: low
DocGo Inc. filed an 8-K on December 20, 2024, to report a Regulation FD Disclosure. The filing does not contain specific financial figures or material events be
Vashovsky Amends DocGo Inc. 13D Filing — SC 13D/A · Nov 29, 2024 Risk: low
Stanley Vashovsky has amended his Schedule 13D filing for DocGo Inc. on November 29, 2024. This amendment relates to his beneficial ownership of the company's c
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
DocGo Inc. Files Q3 2024 10-Q — 10-Q · Nov 7, 2024 Risk: medium
DocGo Inc. filed its 10-Q for the period ending September 30, 2024, reporting on its financial performance. The company, formerly Motion Acquisition Corp., is b
DocGo CFO Departs, Interim Appointed — 8-K · Sep 30, 2024 Risk: medium
DocGo Inc. announced on September 25, 2024, the departure of its Chief Financial Officer, Norman de Jong, effective September 25, 2024. The company also announc
DocGo Inc. Files Q2 2024 10-Q Report — 10-Q · Aug 7, 2024 Risk: medium
DocGo Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly Motion Acquisition Corp., is based in New York and operates in health servi
DocGo Inc. Schedules Shareholder Vote — 8-K · Jun 18, 2024 Risk: low
On June 18, 2024, DocGo Inc. filed an 8-K report to announce a submission of matters to a vote of its security holders. The company, formerly known as Motion Ac
DocGo Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 8, 2024 Risk:
DocGo Inc. (DCGO) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. DocGo Inc. filed its 10-Q report for the period ending March 31, 2024. The filing
DocGo to Acquire Vitality Health for $10M — 8-K · May 7, 2024 Risk: medium
DocGo Inc. announced on May 7, 2024, that it has entered into a definitive agreement to acquire all outstanding equity interests of Vitality Health, Inc. for an
DocGo Inc. Files Proxy Materials — DEFA14A · Apr 25, 2024 Risk: low
DocGo Inc. filed a Definitive Additional Materials (DEFA14A) on April 25, 2024, related to its proxy statement. This filing follows its previous incorporation a
DocGo Inc. Files 8-K Report — 8-K · Apr 10, 2024 Risk: low
On April 8, 2024, DocGo Inc. filed an 8-K report to disclose information under Regulation FD. The filing confirms the company's name, incorporation in Delaware,
DocGo Appoints New CMO, Adds Director — 8-K · Mar 8, 2024 Risk: low
DocGo Inc. announced on March 7, 2024, the appointment of Dr. Yaron Ben-Haim as Chief Medical Officer and the election of Ms. Sarah E. Glickman to its Board of
SC 13G/A Filing — SC 13G/A · Mar 1, 2024
DocGo Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 28, 2024 Risk: low
DocGo Inc. (DCGO) filed a Annual Report (10-K) with the SEC on February 28, 2024. DocGo Inc. filed its 2023 Form 10-K on February 28, 2024, reporting on the fis
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
Deerfield Mgmt Cuts DocGo Stake to 5.3%, Holding 5.32M Shares — SC 13G/A · Feb 12, 2024 Risk: medium
Deerfield Mgmt, L.P. filed an amended SC 13G/A for DocGo Inc. (NASDAQ: DCGO) on February 12, 2024, indicating a change in their beneficial ownership as of Decem
DocGo Enters Material Definitive Agreement on Jan 30 — 8-K · Jan 31, 2024
DocGo Inc. filed an 8-K on January 31, 2024, reporting an event on January 30, 2024, related to an "Entry into a Material Definitive Agreement." This filing ind
BlackRock Amends DocGo Stake Filing as of Dec 31, 2023 — SC 13G/A · Jan 29, 2024
BlackRock Inc. filed an amended SC 13G/A on January 29, 2024, indicating its ownership of DocGo Inc. common stock as of December 31, 2023. This amendment update
DocGo No Longer Emerging Growth Company, Faces Stricter SEC Rules — 8-K · Jan 16, 2024
DocGo Inc. filed an 8-K on January 16, 2024, indicating that it is not an emerging growth company. This matters to investors because emerging growth companies b
DocGo Files 8-K on Operations & Financial Condition — 8-K · Jan 10, 2024
DocGo Inc. filed an 8-K on January 10, 2024, to report on its current operations and financial condition, specifically under Item 2.02 and Item 7.01. This filin

Risk Profile

Risk Assessment: Of DCGO's 22 recent filings, 1 were flagged as high-risk, 7 as medium-risk, and 14 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Docgo INC.'s most recent 10-Q filing (Nov 10, 2025):

Revenue: $247,260,312
Net Income: -$54,026,555
EPS: -$0.49
Cash Position: $73,355,638
Total Assets: $353,782,879

Key Executives

Stanley Vashovsky
Norman de Jong
Michael L. Smith
Dr. Yaron Ben-Haim
Ms. Sarah E. Glickman

Industry Context

DocGo Inc. operates in the healthcare services sector, specifically focusing on mobile diagnostics and medical transportation. The industry is characterized by increasing demand for convenient and accessible healthcare solutions, driven by an aging population and a desire for home-based care. However, it also faces intense competition from established players and new entrants, as well as evolving reimbursement policies and regulatory scrutiny.

Top Tags

corporate-governance (4) · 10-Q (4) · healthcare (4) · amendment (3) · material-agreement (3) · regulation-fd (3) · Mobile Health (2) · Financial Performance (2) · Net Loss (2) · SEC Filing (2)

Key Numbers

Net Loss: $54.0M — For the nine months ended September 30, 2025, a significant decline from $21.0M net income in 2024.
Revenue: $247.3M — For the nine months ended September 30, 2025, a 50.1% decrease from $495.7M in 2024.
Total Impairment Charges: $16.7M — Comprising $8.0M finite-lived intangible asset impairment and $8.7M goodwill impairment, absent in the prior year.
Cash and Cash Equivalents: $73.4M — As of September 30, 2025, down from $89.2M at December 31, 2024.
Total Assets: $353.8M — As of September 30, 2025, a decrease from $455.6M at December 31, 2024.
Diluted EPS: $0.49 — Net loss per share for the nine months ended September 30, 2025, compared to $0.22 diluted EPS in 2024.
Accounts Receivable: $107.0M — Net of allowance for credit loss as of September 30, 2025, down from $210.9M at December 31, 2024.
Net Cash Provided by Operating Activities: $44.9M — For the nine months ended September 30, 2025, a decrease from $57.4M in 2024.
Net Cash Used in Financing Activities: $49.0M — For the nine months ended September 30, 2025, a significant increase from $16.3M in 2024.
Shares Outstanding: 97,813,372 — As of November 7, 2025, indicating a slight decrease from 101,910,883 shares outstanding at December 31, 2024.
Q2 2025 Revenue: $150.5M — Increased 25.1% from Q2 2024
Q2 2025 Net Income: -$5.2M — Shift from $2.1M net income in Q2 2024 to a net loss
Q2 Revenue Growth: 25.1% — Year-over-year increase in revenue for Q2 2025
Six-Month 2025 Revenue: $290.1M — Increased 23.8% from the same period in 2024
Six-Month 2025 Net Income: -$10.8M — Shift from $4.5M net income in the same period of 2024 to a net loss

Forward-Looking Statements

{"claim":"DocGo Inc.'s stock price may experience downward pressure or increased volatility in the short term due to a major institutional investor reducing its stake.","entity":"DocGo Inc.","targetDate":"2024-03-12","confidence":"medium"}
{"claim":"Other institutional investors might re-evaluate their positions in DocGo Inc. following Deerfield Mgmt's reduction.","entity":"DocGo Inc.","targetDate":"2024-04-12","confidence":"low"}

Related Companies

DOCG

Frequently Asked Questions

What are the latest SEC filings for Docgo INC. (DCGO)?

Docgo INC. has 30 recent SEC filings from Jan 2024 to Dec 2025, including 13 8-K, 6 10-Q, 5 SC 13G/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of DCGO filings?

Across 30 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 26 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Docgo INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Docgo INC. (DCGO) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Docgo INC.?

Key financial highlights from Docgo INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for DCGO?

The investment thesis for DCGO includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Docgo INC.?

Key executives identified across Docgo INC.'s filings include Stanley Vashovsky, Norman de Jong, Michael L. Smith, Dr. Yaron Ben-Haim, Ms. Sarah E. Glickman.

What are the main risk factors for Docgo INC. stock?

Of DCGO's 22 assessed filings, 1 were flagged high-risk, 7 medium-risk, and 14 low-risk.

What are recent predictions and forward guidance from Docgo INC.?

Recent forward-looking statements from Docgo INC. include guidance on {"claim":"DocGo Inc.'s stock price may experience downward pressure or increased volatility in the short term due to a m and 1 other predictions.